Retinal degeneration is a major cause of blindness in the USA and often results from a combination of environmental and genetic influences. While progress has been made in identifying some of the pathological factors, a better understanding of how defects lead to disease will result in better treatment. This proposal is based upon the hypothesis that the alkalization of lysosomes in RPE cells contributes to retinal degeneration. Lysosomal alkalinization is known to impede degradation and increase the accumulation of waste material. However, new findings suggest additional ways that alkalinized lysosomes can contribute to retinal degenerations, and these will be confirmed and extended. For example, oxidized lipids are known to escalate degeneration, and new data showing that lysosomal alkalinization leads to increase lipid oxidation in vitro and in vivo will be probed. Microglia and macrophages are also implicated in the disease process, and experiments will probe how lysosomal alkalinization leads to the release of cytokines and ATP, chemoattractants that can recruit the monocytes to RPE cells. This proposal will also update a model of chloroquine retinopathy and demonstrate that lysosomal alkalinization is sufficient to activate molecular and protein markers of retinal degeneration. The chloroquine approach will be applied to genetic models of retinal degenerations to test if lysosomal alkalinization acts synergistically with genetic defects to speed the onset and increase severity of the pathologies. Finally, acidic nanoparticles will be used to reacidify compromised RPE lysosomes in vivo and prevent the loss of photoreceptors in a model of retinal degeneration. In summary, this proposal will examine the mechanisms linking lysosomal alkalinization to disease, demonstrate that lysosomal alkalinization combines with genetic defects to increase pathology, and show that reacidifying lysosomes with acid nanoparticles can prevent the loss of photoreceptors.
Retinal degenerations are major causes of blindness in the USA. This project will investigate how defective lysosomes in RPE cells can lead to damage in these diseases and test the ability of a new treatment to prevent this loss of sight.
|Mitchell, Claire H; Stamer, W Daniel (2016) Dedication of Special Issue on Purinergic Regulation in the Eye to Mortimer M. Civan. J Ocul Pharmacol Ther 32:484|
|Mitchell, Claire H; Civan, Mortimer M (2016) Introduction to Purinergic Regulation in the Eye Special Issue. J Ocul Pharmacol Ther 32:485|
|Lim, Jason C; Lu, Wennan; Beckel, Jonathan M et al. (2016) Neuronal Release of Cytokine IL-3 Triggered by Mechanosensitive Autostimulation of the P2X7 Receptor Is Neuroprotective. Front Cell Neurosci 10:270|
|(2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222|
|Beckel, Jonathan M; Lu, Wennan; Civan, Mortimer M et al. (2016) Treatment of Retinal Disorders with Purinergic Drugs: Beyond Receptors. J Ocul Pharmacol Ther 32:488-489|
|Lu, Wennan; Hu, HuiLing; SÃ©vigny, Jean et al. (2015) Rat, mouse, and primate models of chronic glaucoma show sustained elevation of extracellular ATP and altered purinergic signaling in the posterior eye. Invest Ophthalmol Vis Sci 56:3075-83|
|Beckel, Jonathan M; Daugherty, Stephanie L; Tyagi, Pradeep et al. (2015) Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder. J Physiol 593:1857-71|
|Frost, Laura S; Mitchell, Claire H; Boesze-Battaglia, Kathleen (2014) Autophagy in the eye: implications for ocular cell health. Exp Eye Res 124:56-66|
|Coffey, E E; Beckel, J M; Laties, A M et al. (2014) Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer's disease-linked presenilin 1 A246E mutation can be reversed with cAMP. Neuroscience 263:111-24|
|Sanderson, Julie; Dartt, Darlene A; Trinkaus-Randall, Vickery et al. (2014) Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, MÃ¼ller cells, lens, trabecular meshwork, cornea and lacrimal gland. Exp Eye Res 127:270-9|
Showing the most recent 10 out of 41 publications